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Background: Pathogenic variants in the ﬁlamin C (FLNC) gene are associated with inherited cardiomy-
opathies including dilated cardiomyopathy with an arrhythmogenic phenotype. We evaluated FLNC
variants in arrhythmogenic cardiomyopathy (ACM) and investigated the disease mechanism at a mo-
lecular level.
Methods: 120 gene-elusive ACM patients who fulﬁlled diagnostic criteria for arrhythmogenic right
ventricular cardiomyopathy (ARVC) were screened by whole exome sequencing. Fixed cardiac tissue
from FLNC variant carriers who had died suddenly was investigated by histology and
immunohistochemistry.
Results: Novel or rare FLNC variants, four null and ﬁve variants of unknown signiﬁcance, were identiﬁed
in nine ACM probands (7.5%). In FLNC null variant carriers (including family members, n¼ 16) Task Force
diagnostic electrocardiogram repolarization/depolarization abnormalities were uncommon (19%),
echocardiography was normal in 69%, while 56% had >500 ventricular ectopics/24 h or ventricular
tachycardia on Holter and 67% had late gadolinium enhancement (LGE) on cardiac magnetic resonance
imaging (CMRI). Ten gene positive individuals (63%) had abnormalities on ECG or CMRI that are not
included in the current diagnostic criteria for ARVC. Immunohistochemistry showed altered key protein
distribution, distinctive from that observed in ARVC, predominantly in the left ventricle.
Conclusions: ACM associated with FLNC variants presents with a distinctive phenotype characterized by
Holter arrhythmia and LGE on CMRI with unremarkable ECG and echocardiographic ﬁndings. Clinical
presentation in asymptomatic mutation carriers at risk of sudden death may include abnormalities
which are currently non-diagnostic for ARVC. At the molecular level, the pathogenic mechanism related
to FLNC appears different to classic forms of ARVC caused by desmosomal mutations.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).isease, Institute of Cardiovascular Science, University College London, London, WC1E 6DD, UK.
the reliability and freedom from bias of the data presented and their discussed interpretation.
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
in C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic
urnal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.09.048
C.L. Hall et al. / International Journal of Cardiology xxx (xxxx) xxx2Please cite this article as: C.L. Hall et al., Filam
cardiomyopathy phenotype, International Jo1. Introduction
Efforts to improve early detection of individuals at risk of life
threatening arrhythmia from inherited cardiovascular disease are
ongoing [1]. Identiﬁcation of patients who present with arrhyth-
mias independent of or not explained by recognized causes of
cardiac disease has led to the proposal for the term arrhythmogenic
cardiomyopathy (ACM) [2e4]. The recognition of a number of
inherited arrhythmogenic cardiomyopathies has led to the recent
broader acceptance of this term [1]. Incorporated within this clas-
siﬁcation are patients who present with ventricular arrhythmia in
associationwith right, left or biventricular disease. Arrhythmogenic
Right Ventricular Cardiomyopathy (ARVC) caused by mutations in
desmosomal genes is the most studied of the ACMs with well
established clinical and pathological diagnostic criteria [5,6].
ACM with prominent left ventricle involvement can be indis-
tinguishable from arrhythmogenic forms of dilated cardiomyopa-
thy (DCM) both clinically and genetically [7]. The FLNC gene,
encoding the major cardiac structural protein ﬁlamin C, has been
implicated in inherited forms of cardiomyopathy, including DCM
[8]. Recent studies have reported truncating variants in FLNC as the
cause of DCM with life-threatening ventricular arrhythmia [9,10].
Clinical evaluation of FLNC mutation carriers and molecular char-
acterization of cardiac tissue from a patient carrying a truncating
variant have shown a link between DCM and ARVC, both at the
clinical and cellular level [10]. However, to date, the causal role of
FLNC variants in ACM cases fulﬁlling Task Force diagnostic criteria
for ARVC has not been directly investigated. As a result, the clinical
and molecular phenotype of FLNC-associated ACM is currently
unknown.
In this study, we investigate the clinical characteristics of FLNC
mutation carriers in ACM pedigrees in which the index cases fulﬁl
current diagnostic criteria for ARVC.We also report the distribution
of key proteins in myocardial tissue with FLNC variants and
compare it with that observed in classic forms of the disorder.
2. Methods
2.1. Patient cohort
Genetic screening of 269 ACM patients by targeted next gener-
ation sequencing as described by Lopes et al. [11] identiﬁed a group
of 120 index cases whowere free of potentially pathogenic variants
in major genes associated with cardiomyopathy, arrhythmia and
heart failure syndromes. This gene-elusive cohort underwent
whole exome sequencing in order to identify novel causative ACM
genes.
Patients were referred to the Inherited Cardiovascular Disease
Unit at the Heart Hospital (prior to 2014) and the Barts Cardiac
Centre, St Bartholomew’s Hospital with a suspicion of ACM or with
a premature sudden cardiac death and/or known ACM in their
family. Clinical diagnosis of arrhythmogenic cardiomyopathy was
based on the Task Force diagnostic criteria [6]. Index cases included
in this study had a diagnosis of deﬁnite or borderline ARVC based
on the fulﬁlment of the current Task Force diagnostic criteria for the
disorder [6], or had a possible diagnosis on account of a ﬁrst-degree
relative who died suddenly aged less than 35 years with a post
mortem (PM) diagnosis of ARVC. Detailed clinical evaluation
included medical and family history, 12-lead electrocardiogram
(ECG), signal averaged ECG (SAECG), 24-h ambulatory ECG, stan-
dard 2D transthoracic echocardiogram and cardiac magnetic reso-
nance imaging (CMRI). When appropriate clinical phenotyping andin C variants are associated
urnal of Cardiology, https://dgenetic testing was offered to extended relatives within pedigrees.
This study conforms with the ethical guidelines of the 1975
Declaration of Helsinki and has received approval by the National
Health Service (NHS) Ethics Committees (REC ID: 15/LO/0549, UK)
and CEIC Hospital Virgen de la Arrixaca (Spain) and CEIC Hospital
Universitario y Politecnico La Fe (Spain). Informed written consent
for inclusion in the study was obtained from all participants or, in
cases of minors or deceased individuals, from ﬁrst-degree family
members.
2.2. Whole exome sequencing (WES)
In this study we performed whole exome sequencing on DNA
samples from ACM index cases and family members. DNA from
whole blood, parafﬁn-embedded cardiac tissue and saliva samples
was extracted utilizing kits and protocols from Qiagen and DNA
Genotek. Genomic DNAwas subjected to sample preparation as per
the protocol recommended by Agilent for the SureSelectXT Target
Enrichment for Illumina paired-end multiplexed sequencing
method. Targeted exonic regions were captured using the Agilent
SureSelectXT Human Exon V5 following the manufacturer’s proto-
col. Enriched DNA libraries were exome sequenced on the Illumina
NextSeq500 platform as paired-end 75 base reads at a minimum of
30x coverage. Bioinformatic analysis of WES data including copy
number variation was based on an in-house developed pipeline
(Supplementary material, Appendix).
2.3. Immunohistochemistry
As cardiac tissue was not available from British patients
screened by WES, in order to determine the effects of FLNC muta-
tions at the level of the intercalated disc, postmortem cardiac tissue
from patients with FLNC variants was sourced from a Spanish
clinicopathology consortium. Right and left ventricle (RV and LV)
specimens from eleven sudden cardiac death (SCD) victims with a
diagnosis of arrhythmogenic cardiomyopathy carrying potentially
pathogenic FLNC variants were included in this study. Post-mortem
(PM) examination protocol was in keeping with published guide-
lines. The patients, all male, (aged 16e52, mean age of death 33.5
years) had a diagnosis of ARVC or left dominant arrhythmogenic
cardiomyopathy at autopsy due to the presence of ﬁbrosis and fat
inﬁltration (nine cases) and predominant ﬁbrosis (3 cases). Cardiac
samples from those cases were ﬁxed in formalin and preserved in
parafﬁn blocks. Immunohistochemical analysis of key proteins
previously implicated in the molecular pathogenesis of classical
ARVC in myocardial tissue was carried out based on the protocol
developed by Asimaki et al. [12]. Detailed description of themethod
is provided in the Appendix. Tissue samples from age-matched
individuals with no clinical or pathological evidence of heart dis-
ease were subjected to the same protocol and used as negative
controls (n¼ 5). In summary, RV and LV specimens from each SCD
case were stained for ﬁlamin C, plakoglobin, desmoplakin, con-
nexin 43, synapse-associated protein SAP97 and glycogen synthase
kinase 3b, GSK3b.
3. Results
3.1. FLNC variants
WES of a cohort of 120 gene-elusive ACM index cases identiﬁed
seven novel and two rare FLNC variants (7.5%). They include four
null variants (three nonsense and one splice site variant) which arewith a distinctive clinical and immunohistochemical arrhythmogenic
oi.org/10.1016/j.ijcard.2019.09.048
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Medical Genetics and Genomics (ACMG) guidelines and ﬁve vari-
ants of unknown signiﬁcance (VUS, one in-frame deletion and four
missense variants) [13]. Details of these variants are given in Ap-
pendix Table A1. FLNC variants identiﬁed by WES were conﬁrmed
by Sanger DNA sequencing. There were no FLNC copy number
variants identiﬁed in the cohort.
3.2. Clinical phenotypes of FLNC variant carriers
Index cases carrying FLNC variants had a diagnosis of deﬁnite
(n¼ 4), borderline (n¼ 2) or possible (n¼ 3) ARVC based on the
Task Force diagnostic criteria [6]. All had at least one sudden cardiac
death victim in their extended families ranging from 20 to 71 years
(median 40yrs) and ARVC or arrhythmogenic left ventricular car-
diomyopathy (ALVC) was diagnosed at PM in six deceased family
members (Appendix Table A2).
Segregation analysis and cascade genetic screening with clinical
evaluation of relatives in pedigrees was feasible in the four families
carrying the null FLNC variants (Fig. 1). Detailed clinical features for
FLNC variant carriers in Families A-D are provided in Table 1. For the
VUS variants, pedigree analysis was possible in only two cases
(Families E and F) which carried the p.59_62DLQRdel and p.K2260R
variants respectively (Appendix Figure A1). No family members of
index cases G, H and I were available. Clinical characteristics of FLNC
VUS carriers are given in Appendix Table A3. Therewas no evidence
of skeletal muscle abnormalities in ACM index cases or their rela-
tives and serum creatine kinase levels were normal in those tested.
In addition to ACM index cases, another 26 relatives were clinically
evaluated and genotyped for FLNC variants; fourteen of them were
genotype positive. DNA from two SCD cases was available and those
individuals were also found to be FLNC variants carriers (Fig. 1 and
Figure A1 and Table 1 and A3).
Due to the limited clinical information on pedigrees with FLNC
VUS variants and the ambiguity regarding possible pathogenicity of
such variants, analysis focused on the ACM families with FLNC null
variants (index cases and relatives, n¼ 16). In this cohort the
presence of Task Force diagnostic ECG repolarization and depolar-
ization abnormalities were uncommon, n¼ 2 (12.5%) and n¼ 1
(6.25%) respectively. ECG was unremarkable in 5 genotype positive
individuals (31%), abnormalities in the remaining included low
voltage 5/16 (32%) and poor R wave progression across anterior
chest leads 1/16 (6%). In the majority of cases echocardiogram did
not reveal overt abnormalities (n¼ 11, 69%). Clinical presentation
with palpitation and/or syncope was uncommon, however, 7 pa-
tients (44%) had non sustained VT and/or >500 VES/24 h and 2
(12.5%) presented with sustained VT. Of 15 FLNC null variant car-
riers who had cardiac MRI, the majority (n¼ 10, 67%) showed late
gadolinium enhancement (LGE). Characteristic ECG and CMR im-
ages from a FLNC variant carrier are shown in Fig. 2.
3.3. Immunohistochemical analysis of ﬁxed myocardial tissue
Histological examination of eleven cardiac specimens from
sudden death victims (numbered 1 to 11, Appendix Table A4) car-
rying FLNCmutations was performed at post mortem. Meanweight
was 471.3± 58.9 g. All but two cases had normal internal left ven-
tricular measurements (mean LV diameter 37.4± 11.0mm). Wall
thickness was within normal limits in all hearts (11e13mm).
Evidence of ﬁbrosis was present in both ventricles in ten sam-
ples; ﬁbrofatty replacement was evident in three samples whilst
four specimens showed signs of ﬁbrosis and inﬂammation, mainly
in the left ventricle. Distribution of ﬁbrofatty inﬁltration in the left
ventricle was circumferential in 7 (mesocardial in 4 and sub-
epicardial in 3) and inferolateral subepicardial in 4 cases.Please cite this article as: C.L. Hall et al., Filamin C variants are associated
cardiomyopathy phenotype, International Journal of Cardiology, https://dInﬁltration which was predominant in the inferolateral wall,
extended from the basal to the apical segments. Inﬂammatory in-
ﬁltrates affecting the left ventricle were multifocal in 2 and
extensive in another 2. There was only one specimen (case no 9)
with remarkable inﬂammatory inﬁltrates in the right ventricle,
which also had extensive left involvement. The same sample had no
evidence of ﬁbrosis at PM, however, fat inﬁltration was present.
Characteristic histology images are shown in Appendix Figure A2.
Cardiac specimens used for immunohistochemistry experi-
ments originated from ACM patients with FLNC variants who had
suffered sudden cardiac death. Those included three deletions and
eight single nucleotide substitutions (two splice site, four termi-
nation and twomissense variants). Two unrelated cases carried the
same nonsense mutation: c.5398G> T; p.G1800X. A list of FLNC
variants in ﬁxed tissue samples is given in Appendix Table A4.
Immunoreactive signal for ﬁlamin C was strong and indistin-
guishable from controls in RV samples from ten ACM cases but it
was found to be reduced in LV specimens from all eleven cases. The
signal for plakoglobin was strong and indistinguishable from con-
trols in nine cases in both RV and LV samples. Junctional signal for
Cx43was reduced in two RV samples and six LV samples. Moreover,
signal for the desmosomal protein desmoplakin was found to be
reduced at cell-cell junctions in eight RV samples and ﬁve LV
samples. In contrast, GSK3b was present in the cytosol in all FLNC
cases examined as in control myocardium samples. Finally,
immunoreactive signal for SAP97 appeared reduced in the majority
of RV and LV samples whilst in two cases this protein was only
detected in the sarcomere. Characteristic confocal microscopy im-
ages from case no 6 are displayed in Fig. 3. Immunohistochemistry
data from RV and LV specimens from all eleven cases are sum-
marised in Appendix Figure A3.
4. Discussion
For the ﬁrst time we performed clinical characterization of FLNC
variants in an ACM cohort; previous studies have focused on pure
DCM or DCM with an arrhythmogenic component [8e10]. We
observed marked phenotypic differences in ACM associated with
FLNC null variants compared to classic ARVC caused by desmosomal
gene mutations.
Repolarization (e.g. T wave inversion) and depolarization (such
as prolonged terminal activation duration and epsilon waves) ab-
normalities are considered typical diagnostic features for classic
forms of ARVC [6]. However, in our FLNC cohort only three patients
(19%) had Task Force diagnostic ECG repolarization and depolari-
zation abnormalities. In contrast, the majority of FLNC null variant
carriers (69%) had ECG repolarization and depolarization abnor-
malities, such as right bundle branch block (RBBB) and loss of
inferior R waves, which, in isolation, are not considered diagnostic
criteria [6]. Similarly, standard echocardiographic imaging has been
shown to detect structural abnormalities in the majority of ARVC
patients [14] but 69% of our cases had no detectable echocardio-
graphic disease features. Moreover, the most striking observation
was that MRI showed the presence of LGE with preserved ven-
tricular function in all index cases and the majority of gene positive
family members, a clinical feature which is not currently a diag-
nostic criterion for ARVC [6]. Consequently, in these cases, strict
adherence to the Task Force diagnostic criteria, can lead to in-
dividuals at risk being incorrectly classiﬁed as either unaffected or
being at low risk of complications. This highlights the importance
of genetic evaluation of asymptomatic family members and the
need of more detailed phenotyping targeting recognized features of
particular subtypes of ACM. In this study familial evaluation limited
to ECG and echocardiography would not have identiﬁed the ma-
jority of at-risk individuals whereas signiﬁcant abnormalities werewith a distinctive clinical and immunohistochemical arrhythmogenic
oi.org/10.1016/j.ijcard.2019.09.048
Fig. 1. Pedigrees of ACM families with FLNC variants. Squares indicate males; circles, females; slashes, deceased individuals; black symbols, deﬁnite diagnosis of ARVC based on
current Task Force diagnostic criteria [6] or evidence of ARVC at post mortem; grey symbols, borderline diagnosis of ARVC; hatched symbols, gene positive individuals with possible
diagnosis of ARVC; (þ), positive genotype for FLNC variant; (), negative genotype for FLNC variant; Arrows indicate the index case in each family. ALVC, arrhythmogenic left
ventricular cardiomyopathy; PM, post mortem; SCD, sudden cardiac death. Gene negative individuals with a possible diagnosis of ARVC based solely on family history are depicted
as unaffected.
C.L. Hall et al. / International Journal of Cardiology xxx (xxxx) xxx4detected with ECG monitoring and CMRI, for example individuals
IV:1 (Family A) and II:1 and III:4 (Family C).
In summary, we present the clinical phenotype of FLNC families
with index cases who fulﬁl Task Force diagnostic criteria for ARVC.
It is characterized by predominant LV involvement; frequently non-
diagnostic electrocardiography and echocardiography; frequent
ventricular ectopy or non-sustained VT on 24-h Holter monitoring
and ﬁbrosis (late gadolinium enhancement) on MRI. Notably there
is a high incidence of adverse cardiovascular events, highlighted in
our cohort with a family history of multiple sudden cardiac death
victims at a young age. This clinical pattern appears similar to
emerging experience of other genetically determined arrhythmo-
genic cardiomyopathies caused by mutations in TMEM43, phos-
pholamban, desmin and lamin A/C [15e18]. All may present with
life threatening arrhythmia, myocardial structural abnormalities,
usually predominantly of the left ventricle, though patients have
been reported who fulﬁl Task Force diagnostic criteria. This high-
lights the need for evolution of the current classiﬁcationwith use of
the term ‘arrhythmogenic cardiomyopathy’ which incorporates
ARVC as well as other inherited and acquired forms of ACM. The
recent Heart Rhythm Society guidelines for the diagnosis and
management of arrhythmogenic cardiomyopathy recognize this
evolving scenario [1].
Previous studies have highlighted the importance of immuno-
histochemistry of cardiac tissue from mutation carriers inPlease cite this article as: C.L. Hall et al., Filamin C variants are associated
cardiomyopathy phenotype, International Journal of Cardiology, https://dinvestigating the disease mechanisms related to ACM [19,20]. In
this study, we sought to characterize the molecular proﬁle of ﬁxed
RV and LV specimens from ACM sudden death cases. It has been
previously shown that ﬁlamin C displays a strong localisation at the
intercalated disc that decreases or is completely absent in patients
with restrictive and dilated cardiomyopathy carrying FLNC muta-
tions [8,21]. Here, staining for FLNC showed a decreased immu-
noreactive signal intensity in the left ventricle in all eleven ACM
cases highlighting a predominant left ventricle disease pattern
associated with mutations in this gene. This is consistent with a
recent study that reported reduced immunohistochemical staining
signal for ﬁlamin C in left ventricle samples from an arrhythmo-
genic DCM patient who carried the p.G1891Vfs61X mutation [10].
It is now well established that in ARVC plakoglobin translocates
from the intercalated discs to intracellular pools [19], an observa-
tion that is considered as a “hallmark” of disease pathogenesis [22].
However, the signal for plakoglobin was strong and indistinguish-
able from controls in nine cases (82%) examined in our FLNC cohort
in both left and right ventricular samples. Interestingly, signal for
plakoglobin was decreased in both RV and LV specimens carrying
the two missense variants (p.K35N and p.T160K). However, at
present, the signiﬁcance of this ﬁnding is unclear. Similar to pla-
koglobin mislocalization, the enzyme GSK3b is re-distributed from
the cytosol to the intercalated disc in classic ARVC [23]. However,
none of the eleven FLNC cases examined showed this re-with a distinctive clinical and immunohistochemical arrhythmogenic
oi.org/10.1016/j.ijcard.2019.09.048
Table 1
Clinical characteristics of FLNC null variant carriers in families A-D.
Family
-Individual
FLNC
Genotype
NYHA class/
Symptoms
Age Sex ECG Echocardiography Arrhythmia CMRI Task Force
Diagnostic
Criteria (m, M)/
Diagnosis
Description LVEF
(%)
24 h VE count/type
of arrhythmia
RV EDV
(ml)
RVEF
(%)
LV
EDV
(ml)
LVEF
(%)
LGE distribution
Family A
II:2
(index
case)
p.Arg991X NYHA II 76 F Permanent AF,
low QRS voltage
in limb leads
Late potentials
Borderline LV dilatation with mild LV
systolic dysfunction
50 19,248 Non-
sustained VT
146 49 122 41 Basal lateral LGE 2m and 1M
Deﬁnite
Family A
III:2
p.Arg991X Asymptomatic 44 F Low QRS voltage
in limb leads
Normal biventricular size and function 55
e60
12,935 Normal Normal 172 52 Normal/No LGE 1m and 1M
Borderline
Family A
IV:1
p.Arg991X Palpitations 20 F T-wave
inversion
inferior leads
Normal biventricular size and function 55
e60
69
Sustained VT
presentation, RBBB
morphology
212 54 206 59 Basal lateral sub-epicardial LGE 2m Possible
Family A
IV:2
p.Arg991X Asymptomatic 18 F Unremarkable Normal biventricular size and function 55
e60
1 168 58 184 56 Normal/No LGE 1m Unaffected
Family B
II:1
c.7252-
1G> A
Presyncope 64 M Incomplete RBBB Normal biventricular size and function 55
e60
535 2m Possible
Family B
II:2
(index
case)
c.7252-
1G> A
Asymptomatic 62 M Low QRS voltage Normal biventricular size and function 55
e60
22 210 61 209 65 Sub-epicardial LGE basal-mid
anterolateral and inferolateral
walls
1M* Possible
Family C
II:1
p.L1573X Asymptomatic 76 M Loss of inferior R
waves
Normal biventricular size and function 59 0 147 67 156 64 Basal lateral epicardial LGE None Unaffected
Family C
III:1
(index
case)
p.L1573X Syncope 54 M Low QRS voltage
in limb leads
Non-dilated LV with mild LV dysfunction
RV regional wall motion abnormality
(dyskinetic RVOT and RV free wall)
45
e50
Sustained VT of
LBBB morphology
with superior axis
211 51 183 51 Extensive basal to mid sub-
endocardial LGE in the
anterolateral and inferolateral
walls
1m and 1M
Borderline
Family C
III:4
p.L1573X Palpitations 50 F T wave inversion
V6
Normal biventricular size and function 60 166 Normal Normal 112 70 Equivocal basal LGE 1m Unaffected
Family C
IV:1
p.L1573X Asymptomatic 19 M Unremarkable Normal biventricular size and function 59 3 180 54 173 57 Normal/No LGE None Unaffected
Family C
IV:3
p.L1573X Asymptomatic 26 F Poor R-wave
progression in
anterior leads
Normal biventricular size and function 60 0 141 64 161 60 Normal/No LGE None Unaffected
Family D
II:1
p.Arg482X Asymptomatic 73 M Unremarkable Non-dilated LV and mild LV dysfunction 45 1093 141 41 196 48 Circumferential basal LGE and
mid-inferior and inferolateral
LGE
1m and 1M
Borderline
Family D
II:4
p.Arg482X NYHA II SCD
71
M T-wave
inversion V6
Dilated LV and severe LV dysfunction 35 9249 Non-
sustained VT
Normal normal 257 52 Extensive inferior and
inferolateral subepicardial basal
LGE
2m and 1M
Deﬁnite
Family D
III:2
p.Arg482X Asymptomatic 46 F Unremarkable Normal biventricular size and function 60
e65
6 Non-sustained VT 131 71 149 68 Normal/No LGE 2m Possible
Family D
III:3
p.Arg482X Asymptomatic 43 M Unremarkable Normal biventricular size and function 60
e65
3 161 57 146 68 Subtle streak of non-ischaemic
LGE in the basal inferolateral
wall
1m Unaffected
Family D
III:6
(index
case)
p.Arg482X NYHA II 50 F Low QRS voltage
in precordial
leads
Borderline LV dilatation with mild to
moderate LV systolic dysfunction
40
e45
5197 227 62 187 62 Basal inferolateral and inferior
wall LGE
1m and 1M
Borderline
AF, atrial ﬁbrillation; CMRI, cardiac magnetic resonance imaging; SCD, sudden cardiac death; ECG, electrocardiogram; EDV, end diastolic volume; EF, ejection fraction; NYHA, New York Heart Association classiﬁcation; LBBB, left
bundle branch block; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; LVIDD, end-diastolic internal dimension; m, minor Task Force ARVC diagnostic criterion; M, major Task Force
ARVC diagnostic criterion; RBBB, right bundle branch block; RV, right ventricle; RVEF, right ventricular ejection fraction; RVOT, right ventricle outﬂow tract; VE, ventricular ectopic; VT, ventricular tachycardia; * one major
diagnostic criterion due to family history.
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Fig. 2. ECG and cardiac MR images from individual IV:1 (Family A) who was clinically screened due to family history of ACM. A). Electrocardiogram showing inferior lead T-wave
inversion (III and aVF). B). CMRI two-chamber view of the left ventricle (left image) and short axis view (right image) showing basal lateral subepicardial late gadolinium
enhancement (white arrows). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Immunoreactive signal for the major gap junction protein Cx43
is usually signiﬁcantly depressed at cardiac intercalated discs in
patients with ARVC [23]. In our FLNC cohort, junctional signal for
Cx43 was reduced only in two (20%) RV and six LV (60%) cases.
Considering the advanced disease state and predominant LV
involvement in all our FLNC cases, it is unclear whether Cx43
remodelling played a primary role in ACM pathogenesis or was a
result of the histological changes in the myocardium. The signal for
the desmosomal protein desmoplakin was found to be reduced at
cell-cell junctions mainly in RV samples (80%) and when DSP
staining intensity was reduced in the left ventricle, the corre-
sponding RV signal for the same case was also reduced. Altered
desmoplakin localisation has been reported in left dominant
arrhythmogenic cardiomyopathy [24] and, as our FLNC cases had a
predominantly left dominant pattern of disease, the observed
reduction of desmoplakin signal is in line with this phenotype.
SAP97 is a membrane-associated guanylate kinase reported to
show consistently decreased immunohistochemistry staining in-
tensity in both the sarcomeric and junctional pools in the
myocardium of desmosomal ACM patients independently of the
speciﬁc causative mutation [25]. In our cohort SAP97 was reduced
in the majority of RV and LV specimens whilst in two cases SAP97
signal was detectable in the sarcomeres but not at the intercalated
discs. This ﬁnding is consistent with previous reports onmyocardial
samples from patients with end-stage ischemic, dilated andPlease cite this article as: C.L. Hall et al., Filamin C variants are associated
cardiomyopathy phenotype, International Journal of Cardiology, https://dhypertrophic cardiomyopathy [25].
Overall, we observed a speciﬁc localisation pattern in our cohort
for three proteins: FLNC signal was reduced in all cases; plakoglobin
signal was normal in the largemajority of RV and LV specimens and
GSK3b signal was normal in all cases tested. All these ﬁndings point
to a disease pattern different to classic ARVC and are consistent
with the hypothesis that ACM associated with FLNC variants pre-
sents with a left dominant arrhythmogenic cardiomyopathy
phenotype which may manifest via a different mechanism to
typical right ventricular arrhythmogenic cardiomyopathy. Begay
et al., 2018 observed similar immunohistochemistry results to our
data for a patient with the p.G1891Vfs61X FLNC mutation, namely
normal plakoglobin immunostaining signal, typical GSK3b cyto-
plasmic distribution and reduced DSP signal compared to control
samples [10].
Collectively, our analysis suggests that the clinical andmolecular
“signature’ of FLNC cardiomyopathy is distinct to that of ARVC.
These results indicate that these two clinical entities reﬂect
different molecular mechanisms of pathogenesis.
4.1. Limitations
This study is limited by the small number of recruited FLNC
variant carriers which, in part, is attributed to the low frequency of
causative FLNC variants in ACM and the high genetic heterogeneity
that characterizes the disorder. As it is common in studies ofwith a distinctive clinical and immunohistochemical arrhythmogenic
oi.org/10.1016/j.ijcard.2019.09.048
Fig. 3. Immunohistochemistry staining of parafﬁn-embedded cardiac specimens from case no 6 carrying the p.Y705X FLNC variant. Top panel, control sample; middle panel, RV
sample; bottom panel, LV sample. Immunoreactive signal for plakoglobin and GSK3b at the intercalated discs appear normal compared control samples. Signal for FLNC appears
normal in the RV but reduced in the LV. Signal for connexin 43, desmoplakin, and SAP97 is reduced in both RV and LV. N-cadherin is used as a marker of tissue quality and is normal
in all specimens. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
C.L. Hall et al. / International Journal of Cardiology xxx (xxxx) xxx 7cardiomyopathy patients, small family sizes have restricted our
ability to perform extensive segregation analysis in all FLNC cases.
Immunohistochemical analysis relied on the availability of
parafﬁn ﬁxed tissue. The challenges in collecting human heart
samples arewell known. Therefore, this study was also hindered by
limited quantity of tissue for each case and some samples were not
immunostained for a complete set of proteins.5. Conclusion
ACM related to FLNC variants presents with a distinctive
phenotype that may not be recognized by current Task Force ARVC
diagnostic criteria or by familial evaluation limited to ECG or
echocardiography. Physicians should be aware of “non-diagnostic”
disease features in asymptomatic gene positive individuals.
The molecular mechanism of pathogenesis of this form of ACM
is markedly different to classic ARVC and does not involve mis-
localization of plakoglobin or GSK3b.Funding
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